A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 598-603

  Tao, Sha ^a   Wang, Zhong ^b,c   Feng, Junjie ^b,c   Hsu, Fang Chi ^b,c   Jin, Guangfu ^b,c   Kim, Seong Tae ^b,c   Zhang, Zheng ^b,c   Gronberg, Henrik ^d   Zheng, Lilly S ^b,c   Isaacs, William B ^e   Xu, Jianfeng ^a,b,c   Sun, Jielin ^b,c  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Center for Cancer Genomics   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE SYK; SOMATOMEDIN B;

ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE DELETION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME; HUMAN; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863255226     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr316     Document Type: Article

References (51)

1. Amundadottir, L.T. et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat. Genet., 38, 652-658.
2. Gudmundsson, J. et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet., 39, 631-637.
3. Yeager, M. et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet., 39, 645-649.
4. Gudmundsson, J. et al. (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet., 39, 977-983.
5. Duggan, D. et al. (2007) Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst., 99, 1836-1844.
6. Thomas, G. et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet., 40, 310-315.
7. Gudmundsson, J. et al. (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet., 40, 281-283.
8. Eeles, R.A. et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet., 40, 316-321.
9. Yeager, M. et al. (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat. Genet., 41, 1055-1057.
10. Gudmundsson, J. et al. (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet., 41, 1122-1126.
11. Eeles, R.A. et al. (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet., 41, 1116-1121.
12. Sun, J. et al. (2008) Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate, 68, 691-697.
13. Hsu, F.C. et al. (2009) A novel prostate cancer susceptibility locus at 19q13. Cancer Res., 69, 2720-2723.
14. Sun, J. et al. (2009) Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res., 69, 10-15.
15. Zheng, S.L. et al. (2009) Two independent prostate cancer risk-associated loci at 11q13. Cancer Epidemiol. Biomarkers Prev., 18, 1815-1820.
16. Kote-Jarai, Z. et al. (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol. Biomarkers Prev., 17, 2052-2061.
17. Chang, B.L. et al. (2011) Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol. Biomarkers Prev., 20, 23-32.
18. Zheng, S.L. et al. (2010) Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate, 70, 425-432.
19. Yamada, H. et al. (2009) Replication of prostate cancer risk loci in a Japanese case-control association study. J. Natl Cancer Inst., 101, 1330-1336.
20. Lindstrom, S. et al. (2011) Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS One, 6, e17142.
21. Mackay, T.F. (2001) Quantitative trait loci in Drosophila. Nat. Rev. Genet., 2, 11-20.
22. Williams, S.M. et al. (2004) The use of animal models in the study of complex disease: all else is never equal or why do so many human studies fail to replicate animal findings? Bioessays, 26, 170-179.
23. Routman, E.J.C. et al. (1997) Gene effects on a quantitative trait: two-locus epistatic effects measured at microsatellite markers and at estimated QTL. Evolution, 51, 1654-1662.
24. Ciampa, J. et al. (2011) Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Res., 71, 3287-3295.
25. Xu, J. et al. (2010) Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc. Natl Acad. Sci. USA, 107, 2136-2140.
26. Marchini, J. et al. (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet., 39, 906-913.
27. Purcell, S. et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet., 81, 559-575.
28. Price, A.L. et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet., 38, 904-909.
29. Manning, A.K. et al. (2011) Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP x environment regression coefficients. Genet. Epidemiol., 35, 11-18.
30. Cordell, H.J. (2009) Detecting gene-gene interactions that underlie human diseases. Nat. Rev. Genet., 10, 392-404.
31. Janssen, J.W. et al. (2000) Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32). Blood, 95, 2691-2698.
32. Janssen, J.W. et al. (2002) MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas. J. Hum. Genet., 47, 460-464.
33. Janssen, J.W. et al. (2002) MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer. Int. J. Cancer, 102, 608-614.
34. Specht, K. et al. (2004) Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood, 104, 1120-1126.
35. Moss, A.C. et al. (2006) ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. Biochem. Biophys. Res. Commun., 345, 216-221.
36. Hatch, E.M. et al. (2010) Cep152 interacts with Plk4 and is required for centriole duplication. J. Cell Biol., 191, 721-729.
37. Kalay, E. et al. (2011) CEP152 is a genome maintenance protein disrupted in Seckel syndrome. Nat. Genet., 43, 23-26.
38. Cui, H. et al. (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science, 299, 1753-1755.
39. Zhao, R. et al. (2009) Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis, 30, 2117-2122.
40. Vorwerk, P. et al. (2003) Loss of imprinting of IGF-II gene in children with acute lymphoblastic leukemia. Leuk. Res., 27, 807-812.
41. Jarrard, D.F. et al. (1995) Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin. Cancer Res., 1, 8.
42. Veronese, A. et al. (2010) Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res., 70, 3140-3149.
43. Hao, J. et al. (2011) MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett., 585, 207-213.
44. Mohr, F. et al. (2011) TET genes: new players in DNA demethylation and important determinants for stemness. Exp. Hematol., 39, 272-281.
45. Lorsbach, R.B. et al. (2003) TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia, 17, 637-641.
46. Abdel-Wahab, O. et al. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 114, 144-147.
47. Coopman, P.J. et al. (2006) The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett., 241, 159-173.
48. Ma, L. et al. (2010) The relationship between methylation of the Syk gene in the promoter region and the genesis of lung cancer. Clin. Lab., 56, 407-416.
49. Yuan, Y. et al. (2001) Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res., 61, 5558-5561.
50. Wang, B. (2011) Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners. Sci. Signal., 175, pe28-pe30.
51. Shan, Z. et al. (2004) Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer. Oncogene, 23, 6612-6620.